Andrew Mant

Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, <i>EGFR</i> –Mutant, Metastatic Nonsquamous Non–Small Cell Lung Cancer

James Chih‐Hsin Yang, Dae Ho Lee, Jong‐Seok Lee et al. · Journal of Clinical Oncology · 2024 · 142 citations · Full text

Medicine, Oncology, Pharmacology +14

Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination

Ana Arance, Luis de la Cruz‐Merino, Teresa M. Petrella et al. · Journal of Clinical Oncology · 2022 · 127 citations

Medicine, Oncology, Pharmacotherapy +17

Combined ipilimumab and nivolumab first‐line and after BRAF‐targeted therapy in advanced melanoma

Robert M. Mason, Helen Clare Dearden, Bella Nguyen et al. · Pigment Cell & Melanoma Research · 2019 · 62 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Efficacy and safety of cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma

Philip R. Clingan, Rahul Ladwa, Daniel Brungs et al. · Journal for ImmunoTherapy of Cancer · 2023 · 44 citations · Full text

Pharmacy, Oncology, Pharmacology +17

Diabetes associated with immune checkpoint inhibition: presentation and management challenges

Anna Galligan, Wen Xu, Spiros Fourlanos et al. · Diabetic Medicine · 2018 · 32 citations

Life Sciences, Endocrinology, Immunology +17